To: Lowell Schiller, Principal Associate Commissioner for Policy, U.S. Food and Drug Administration
"Several endocrine conditions, including acromegaly, adrenocortical carcinoma, growth hormone deficiency, Cushing’s syndrome, and familial chylomicronemia syndrome (FCS), qualify as rare diseases, and patients still lack effective treatments for many of these and other conditions. We enthusiastically support the Rare Diseases Cures Accelerator and welcome the opportunity to participate in a global clinical trial network for rare diseases. Our comments are aimed at ensuring the immediate and long-term success of such an initiative."
Join us in lending your voice to our online advocacy to support our policy priorities, endocrinology, and science. Contact your U.S representatives or European Members of Parliament through our online platform. Take action and make a difference today.